Lineage Cell Therapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdateBusiness Wire • 05/11/23
Lineage Cell Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023Business Wire • 05/04/23
RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular DegenerationBusiness Wire • 04/26/23
Lineage and the Christopher & Dana Reeve Foundation Proudly Present the 1st Annual Spinal Cord Injury Investor SymposiumBusiness Wire • 03/30/23
RG6501 (OpRegen®) Phase 1/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation SummitBusiness Wire • 03/20/23
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateBusiness Wire • 03/09/23
RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Eyal Banin, M.D., Ph.D.Business Wire • 03/06/23
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 9, 2023Business Wire • 03/02/23
Lineage Enters Into Option and License Agreement With Eterna Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology IndicationsBusiness Wire • 02/22/23
Lineage Provides Update on Auditory Neuronal Cell Transplant Program for the Treatment of Hearing LossBusiness Wire • 02/08/23
Lineage to Present at BTIG Ophthalmology Day and the Cantor Fitzgerald Medical & Aesthetic Dermatology, Ophthalmology & MedTech ConferenceBusiness Wire • 11/29/22
Lineage Announces Launch of Phase 2a Study by Genentech of RG6501 (OpRegen®) in Patients With Geographic Atrophy Secondary to Age-Related Macular DegenerationBusiness Wire • 11/28/22
Lineage Cell Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business UpdateBusiness Wire • 11/10/22
Lineage Cell Therapeutics to Report Third Quarter 2022 Financial Results and Provide Business Update on November 10, 2022Business Wire • 11/03/22
Lineage Announces Notice of Allowance of Two Patents Covering Processes for Manufacturing Allogeneic Oligodendrocyte Progenitor and Retinal Pigmented Epithelium CellsBusiness Wire • 10/10/22
Lineage to Present at Alliance for Regenerative Medicine 2022 Cell & Gene Meeting on the MesaBusiness Wire • 10/04/22
Lineage Establishes New R&D Facility in U.S. and Expands Current GMP Manufacturing Facility in IsraelBusiness Wire • 10/03/22